Effect of platelet-rich plasma combined with tranexamic acid in the treatment of melasma and its effect on the serum levels of vascular endothelial growth factor, endothelin-1 and melatonin

Abstract

Objective: To investigate the effect of platelet-rich plasma (PRP) combined with tranexamic acid (TXA) in the treatment of melasma and its effect on the serum levels of vascular endothelial growth factor (VEGF), endothelin-1 (ET-1) and melanin stimulating hormone (MSH).
 Methods: We retrospectively analyzed clinical data of 80 patients with melasma treated in our hospital from January 2020 to June 2021. Patients (n=38) in the control group received simple oral TXA treatment. Patients (n=42) in the study group received PRP combined with oral TXA treatment. We assessed the treatment effects on the serum biochemical index levels, the adverse reactions, and the recurrence rates in the two groups.
 Results: The total efficacy of the study group (90.48%) was higher than that of the control group (73.68%) (p<0.05). After the treatment, the levels of serum VEGF increased and the levels of ET-1 and MSH decreased in both groups, but the changes in the study group were more pronounced than those in the control group (p<0.05). We found similar incidences of the adverse reaction in the study group (7.14%) and the control group (5.26%; p>0.05). The disease recurrence rates between the two groups three months after the treatment were similar (p>0.05). However, the disease recurrence rate in the study group (4.76%) was lower than that in the control group (21.05%) 6 months after treatment (p<0.05).
 Conclusions: PRP combined with oral TXA can improve the treatment effect of TXA alone in the treatment of melasma, maintaining normal levels of VEGF, ET-1 and MSH, reducing disease recurrences.
 doi: https://doi.org/10.12669/pjms.38.8.6786
 How to cite this:Zhang C, Wu T, Shen N. Effect of platelet-rich plasma combined with tranexamic acid in the treatment of melasma and its effect on the serum levels of vascular endothelial growth factor, endothelin-1 and melatonin. Pak J Med Sci. 2022;38(8):2163-2168. doi: https://doi.org/10.12669/pjms.38.8.6786
 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study

“…In a study by Zhang et al, who investigated the effect of platelet-rich plasma (PRP) combined with tranexamic acid (TXA) in the treatment of melasma and its effect on the serum levels of vascular endothelial growth factor (VEGF), endothelin-1 (ET-1), and melanin-stimulating hormone (MSH), they reported that PRP combined with TXA can improve the treatment outcome, maintaining normal levels of VEGF, ET-1 and MSH, and reducing the recurrence rate [ 22 ].…”

Effect of ranibizumab combined with laser photocoagulation in the treatment of diabetic macular edema

“…5,6 Study has found that vascular endothelial growth factor (VEGF) can stimulate angiogenesis, increase its permeability, and accelerate the progress of DME. 7 Therefore, anti-VEGF drugs have emerged as potential agents to improve the therapeutic effect of DME. 7,8 Ranibizumab is a second-generation humanized recombinant monoclonal antibody fragment against VEGF, which can selectively bind to VEGF and inhibit endothelial cell proliferation, thereby exerting therapeutic effects.…”

“…7 Therefore, anti-VEGF drugs have emerged as potential agents to improve the therapeutic effect of DME. 7,8 Ranibizumab is a second-generation humanized recombinant monoclonal antibody fragment against VEGF, which can selectively bind to VEGF and inhibit endothelial cell proliferation, thereby exerting therapeutic effects. 9,10 Several studies have suggested the superiority of combining laser treatment with anti-VEGF therapy in patients with DME.…”

Clinical changes of serum melatonin and ICAM-1 levels in patients with basal ganglia hypertensive intracerebral hemorrhage

“… 6 Serum melatonin is the strongest endogenous free radical scavenger and its basic function is to participate in the antioxidant system and prevent cells from oxidative damage. 7 Animal experiment has shown that melatonin has a good protective effect on ischemic brain injury. 8 Intercellular adhesion molecule-1(ICAM-1), a transmembrane glycoprotein, participates in physiological and pathological processes such as cell signal transduction and activation, cell tissue growth and differentiation, immune response, inflammatory response, angiogenesis, and tumor metastasis.…”